Episteme Prognostics’ mission is to fundamentally transform how cancer is treated. We are developing precision diagnostics designed to help identify which patients are most likely to benefit from cancer therapies. Our goal is to ensure that chemotherapy is given only to patients who are likely to benefit, while guiding others toward the best alternative treatment options.
Predicting treatment response before treatment begins
The Problem:
Chemotherapy remains a cornerstone of cancer treatment. But not every patient responds.
- Each year, 10-13 million cancer patients receive chemotherapy.
- 7-9 million patients do not respond.
Treatment failure can lead to poorer outcomes, fewer options, and an immense emotional and financial burden.
Episteme is building the future of precision oncology.
Our First Application is PancEpistemeDx™
Our first planned diagnostic to predict chemotherapy response in pancreatic cancer using tumor chromatin accessibility signatures.
-
Predict Response
Identify patients unlikely to respond to chemotherapy.
-
Inform Treatment
Provide actionable information before treatment decisions are made.
-
Advance Precision Oncology
Extend our approach to additional therapies and cancer types.
Beyond Pancreatic Cancer
One platform. Multiple applications.
-
Cancer Therapy Selection
Improve outcomes by matching patients to the right therapy.
-
Biopharma Drug Development
Accelerate clinical development and identify responsive populations.
-
Companion Diagnostics
Develop diagnostic solutions for targeted and epigenetic therapies.